The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…
HOME > BUSINESS
BUSINESS
- Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
June 11, 2021
- NanoCarrier Gene Therapy VB-111 Enters PIII in Japan
June 11, 2021
- Global Pharma Market Grows to US$1.18 Trillion in 2020, with Humira Maintaining No. 1 Title: IQVIA
June 11, 2021
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Takeda Boasts 10-Plus Immune-Harnessing Compounds in Early Pipeline: Oncology Update
June 10, 2021
- Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
- Kitasato Institute, Meiji Kick Off R&D of Ivermectin Derivatives-Based COVID-19 Meds
June 10, 2021
- Nippon Chemiphar, Sumitomo Dainippon Team Up on Antidepressant R&D
June 10, 2021
- Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
- Novo, Chiba University, Asahi City Join Hands to Combat Diabetes
June 9, 2021
- Takeda Chips in for Govt’s Workplace COVID-19 Immunization Drive
June 9, 2021
- Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
- FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
- Japan Ethical Drug Sales Down 2.4% in April: Crecon
June 8, 2021
- Keytruda Retrieves Top-Selling Crown in Japan in May: Encise
June 8, 2021
- Daiichi Sankyo’s ADC U3-1402 Scores 39% ORR for EGFR-Mutated NSCLC in PI
June 8, 2021
- Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
- Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
- Reps’ Face-to-Face Meetings Up 60% YOY in April, but Fall Shy of Prepandemic Level: Intage
June 7, 2021
- AstraZeneca Launches Exploratory Study to Predict Onset of ILD in NSCLC Patients on Imfinzi
June 7, 2021
ページ
Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…